To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma

Inclusion Criteria: * All the criteria listed in the following need to be met before patient inclusion. 1. Histologically confirmed inoperable or metastatic melanoma (stage IIIc or IV). 2. Progressive disease after standard treatment with PD-1 check-point inhibition or combination of aforementioned with CTLA-4 check-point inhibition. 3. Age: 18 - 75 years at time of signed Informed consent. 4. ECOG performance status of ≤ 1 (Appendix 2). 5. Is fit for tumor resection and has at least one lesion (\> 1 cm3) available for surgical resection for manufacture of TIL. 6. At least one measurable parameter in accordance with RECIST 1.1 -criteria (excluding lesion to be resected). 7. LVEF assessment with documented LVEF ≥50% by either TTE (transthoracic echocardiography) or MUGA (multigated acquisition scan). 8. Sufficient organ function, including: * Absolute neutrophil count (ANC) ≥ 1.500 /µl * Leucocyte count ≥ lower normal limit * Platelets ≥ 100.000 /µl and \<700.000 /µl * Hemoglobin ≥ 6.0 mmol/l * eGFR \> 70 ml/min\* * S-bilirubin ≤ 1.5 times upper normal limit (Exception: Subjects with liver metastasis ≤ 2.5 × ULN) * ASAT/ALAT ≤ 2.5 times upper normal limit (Exception: Subjects with liver metastasis ≤ 5.0 × ULN) * Alkaline phosphatase ≤ 5 times upper normal limit * Lactate dehydrogenase ≤ 5 times upper normal limit * Sufficient coagulation: APPT\<40 and INR\<1.5 * \* In selected cases it can be decided to include a patient with an eGFR \< 70 ml/min with the use of a reduced dose of chemotherapy. 9\. Signed statement of consent after receiving oral and written study information 10. Willingness to participate in the planned controls and capable of handling toxicities. 11\. Subject must receive T-cell therapy as the next therapy following tumor resection, unless bridging therapy is administered: * Bridging therapy is discouraged. However, if in the opinion of the Investigator, the subject requires immediate therapy after tumor resection, the subject may receive bridging therapy for the period during which the subject is awaiting the manufacture of TIL-infusion product. Bridging therapy may be a continuation of the therapy the subject was receiving prior to tumor resection or may be a new therapy. * Following this bridging therapy, the subject must adhere to the mandatory washout periods (exclusion criterion 1) and must continue to have measurable disease prior to receiving T-cell therapy. 12\. Age and Reproductive Status: * Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test AND must agree to use an effective method of contraception starting at the first dose of chemotherapy for at least 12 months. WOCBP must also agree to refrain from egg donation, storage, or banking during these same time periods. The following are considered safe methods of contraception: * Hormonal anticonception (birth control pills, spiral, depot injection with gestagen, subdermal implantation, hormonal vaginal ring and transdermal depot patch) * Intrauterine device * Surgical sterilization * Surgical sterilization of male partner with verification of no sperm after the procedure * Menopause (for more than 12 months) o Male subjects must be surgically sterile or agree to use a double-barrier contraception method or abstain from sexual activity with an WOCBP starting at the first dose of chemotherapy and for 6 months thereafter. Male subjects must also agree to refrain from sperm donation, storage, or banking. Exclusion Criteria: * Patients will be excluded if they meet one of the criteria's listed below 1. Subject has received or plans to receive the following therapy/treatment prior to tumor resection (TR) or lymphodepleting chemotherapy (LDC): * Cytotoxic chemotherapy: Washout period 3 weeks before TR and LDC * Small molecules/TKI: Washout period 1 week before TR and LDC * Immune therapy (monoclonal AB therapy, CPI and biologics): 2 weeks before TR and LDC * Prior T-cell therapy, including gene therapy using an integrating vector * Corticosteroids at dose equivalent \> 10 mg prednisone or any other immunosuppressive therapy. 2 weeks before TR and LDC. Note: Use of topical steroids is not an exclusion * Investigational treatment: 4 weeks or 5 half-lives, whichever is shorter before TR and LDC * Radiation to the pelvis and/or multiple bones containing ≥ 25% of bone marrow: 4 weeks before TR and LDC * Whole brain radiotherapy or brain stereotactic radiosurgery: 4 weeks before TR and LDC * Radiotherapy to the target lesions: 3 months prior to TIL-infusion. A lesion with unequivocal progression post-radiotherapy may be considered a target lesion. 2. A history of prior malignancies. Patients treated for another malignancy can participate if they are without signs of disease for a minimum of 2 years after treatment. Subjects with curatively treated ductal carcinoma in situ (DCIS or LCIS) breast cancer for which they are taking hormonal therapy is acceptable. Resectable squamous or basal cell carcinoma of the skin is acceptable. 3. Patients with metastatic ocular/mucosal or other non-cutaneous melanoma. Unknown primary melanoma is eligible. 4. Toxicity from previous anti-cancer therapy must have resolved to ≤ Grade 1 or baseline prior to enrollment (except for non-clinically significant toxicities e.g., alopecia, vitiligo). Subjects with Grade 2 toxicities who are deemed stable or irreversible (e.g., peripheral neuropathy) can be enrolled. 5. Patients who have more than 2 CNS metastases or who have any CNS lesion that is symptomatic, greater than 1 cm in diameter or show significant surrounding edema on MRI scan will not be eligible until they have been treated and demonstrated no clincal or radiologic CNS progression for at least 2 months. 6. The following patients will be excluded because of inability to receive high dose interleukin-2